Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Bee pollen (Corbiculae/Obnozhka) is raw flower pollen collected by bees, containing amino acids, flavonoids, vitamins, and enzymes. Generally well tolerated in non-allergic individuals. Severe allergic reactions including anaphylaxis are documented — contraindicated in bee product or pollen allergy. Contains natural coumarin derivatives that may mildly potentiate anticoagulant therapy. Avoid in pregnancy. Microbial and pesticide contamination is a quality concern; choose tested sources.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Specialty
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Bee Pollen indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:09
Evidence Distribution
-
Observational / other LOW evidence YELLOWMulti-Strain Probiotic and Bee Pollen Supplementation Attenuates CCl(4)-Induced Altered Intestinal Tight Junctions in Rodents. ↗Alsayari N et al.. Multi-Strain Probiotic and Bee Pollen Supplementation Attenuates CCl(4)-Induced Altered Intestinal Tight Junctions in Rodents.. Curr Issues Mol Biol. 2026. PMID:41899461.PMID 41899461 ↗Journal Curr Issues Mol BiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41899461/
-
Observational / other LOW evidence YELLOWEncapsulation of Bee Pollen Phenolics with u03b2-Cyclodextrin: Effects on Antioxidant Activity, Antimicrobial Properties, and Digestive Stability. ↗Akdas A et al.. Encapsulation of Bee Pollen Phenolics with u03b2-Cyclodextrin: Effects on Antioxidant Activity, Antimicrobial Properties, and Digestive Stability.. Foods. 2026. PMID:41897769.PMID 41897769 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41897769/
-
Observational / other LOW evidence YELLOWPhenolamide Extract of Apricot Bee Pollen Alleviates DSS-Induced Ulcerative Colitis in Mice by Reducing Oxidative Stress, Modulating Inflammation, and Regulating Gut Microbiota. ↗Liu W et al.. Phenolamide Extract of Apricot Bee Pollen Alleviates DSS-Induced Ulcerative Colitis in Mice by Reducing Oxidative Stress, Modulating Inflammation, and Regulating Gut Microbiota.. Antioxidants (Basel). 2026. PMID:41897549.PMID 41897549 ↗Journal Antioxidants (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41897549/
-
Observational / other LOW evidence YELLOWSurface-to-Bulk Elemental Profiling and Melissopalynological Characterization of Monofloral Bee Pollens: Implications for Nutritional Value and Health Risk Assessment. ↗u015eeker ME et al.. Surface-to-Bulk Elemental Profiling and Melissopalynological Characterization of Monofloral Bee Pollens: Implications for Nutritional Value and Health Risk Assessment.. Biol Trace Elem Res. 2026. PMID:41857348.PMID 41857348 ↗Journal Biol Trace Elem ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41857348/
-
Observational / other LOW evidence YELLOWEffect of bee pollen on viability of starter culture bacteria in probiotic yogurt. ↗u00c7iftu00e7i M et al.. Effect of bee pollen on viability of starter culture bacteria in probiotic yogurt.. An Acad Bras Cienc. 2026. PMID:41849490.PMID 41849490 ↗Journal An Acad Bras CiencYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41849490/
-
Observational / other LOW evidence YELLOWImpact of Direct-Fed Microorganism Syrup on Honey Bee (Apis mellifera L.) Hypopharyngeal Gland Development, Protein Digestibility and Gut Microbiota Composition. ↗Praphawilai P et al.. Impact of Direct-Fed Microorganism Syrup on Honey Bee (Apis mellifera L.) Hypopharyngeal Gland Development, Protein Digestibility and Gut Microbiota Composition.. Animals (Basel). 2026. PMID:41828914.PMID 41828914 ↗Journal Animals (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41828914/
-
Observational / other LOW evidence YELLOWEffects of Bee Bread (Perga) on Pro-Inflammatory Cytokine Levels and Histopathological Alterations in the Liver and Kidneys of Streptozotocin-Induced Diabetic Rats. ↗Akman N et al.. Effects of Bee Bread (Perga) on Pro-Inflammatory Cytokine Levels and Histopathological Alterations in the Liver and Kidneys of Streptozotocin-Induced Diabetic Rats.. Biology (Basel). 2026. PMID:41823808.PMID 41823808 ↗Journal Biology (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41823808/
-
Observational / other LOW evidence YELLOWDo Buzz-Pollinating Bumble Bees Facilitate Honey Bee Pollination in Southern Highbush Blueberry Through Increasing Pollen Release? ↗Ternest JJ et al.. Do Buzz-Pollinating Bumble Bees Facilitate Honey Bee Pollination in Southern Highbush Blueberry Through Increasing Pollen Release?. Ecol Evol. 2026. PMID:41810096.PMID 41810096 ↗Journal Ecol EvolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41810096/
-
Observational / other LOW evidence YELLOWHoney and Bee Products: Characterization, Bioactivities, and Authenticity. ↗Osu00e9s SM et al.. Honey and Bee Products: Characterization, Bioactivities, and Authenticity.. Foods. 2026. PMID:41750839.PMID 41750839 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41750839/
-
Observational / other LOW evidence YELLOWBiomonitoring with bees and bee products: multielement profiles including technology-critical elements. ↗Trimmel S et al.. Biomonitoring with bees and bee products: multielement profiles including technology-critical elements.. Monatsh Chem. 2026. PMID:41716814.PMID 41716814 ↗Journal Monatsh ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41716814/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Bee Pollen. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Bee Pollen
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.